Combining a noble gas with radiotherapy

• Verfasst von: Büttner, Thomas [VerfasserIn]
• Verfasst von: Maerevoet, Marielena K. E. [VerfasserIn]
• Verfasst von: Giordano, Frank Anton [VerfasserIn]
• Verfasst von: Veldwijk, Marlon Romano [VerfasserIn]
• Verfasst von: Herskind, Carsten [VerfasserIn]
• Verfasst von: Ruder, Arne Mathias [VerfasserIn]
• Titel: Combining a noble gas with radiotherapy
• Titelzusatz: glutamate receptor antagonist xenon may act as a radiosensitizer in glioblastoma
• Verf.angabe: Thomas Büttner, Marielena K. E. Maerevoet, Frank A. Giordano, Marlon R. Veldwijk, Carsten Herskind and Arne Mathias Ruder
• E-Jahr: 2024
• Jahr: 30 January 2024
• Umfang: 10 S.
• Fussnoten: Gesehen am 10.06.2024
• Titel Quelle: Enthalten in: Radiation oncology
• Ort Quelle: London : BioMed Central, 2006
• Jahr Quelle: 2024
• Band/Heft Quelle: 19(2024), Artikel-ID 16, Seite 1-10
• ISSN Quelle: 1748-717X
• DOI: doi:10.1186/s13014-023-02395-1
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: AMPA
• Sach-SW: Clonogenic assay
• Sach-SW: Glioblastoma
• Sach-SW: Glioma
• Sach-SW: Glutamate receptors
• Sach-SW: Memantine
• Sach-SW: NMDA
• Sach-SW: Radiation sensitizer
• Sach-SW: Radiotherapy
• Sach-SW: Xenon
• K10plus-PPN: 1890974021

Abstract

Background: Ionotropic glutamate receptors α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) and N-methyl-D-aspartate receptor (NMDAR) modulate proliferation, invasion and radioresistance in glioblastoma (GB). Pharmacological targeting is difficult as many in vitro-effective agents are not suitable for in patient applications. We aimed to develop a method to test the well tolerated AMPAR- and NMDAR-antagonist xenon gas as a radiosensitizer in GB. Methods: We designed a diffusion-based system to perform the colony formation assay (CFA), the radiobiological gold standard, under xenon exposure. Stable and reproducible gas atmosphere was validated with oxygen and carbon dioxide as tracer gases. After checking for AMPAR and NMDAR expression via immunofluorescence staining we performed the CFA with the glioblastoma cell lines U87 and U251 as well as the non-glioblastoma derived cell line HeLa. Xenon was applied after irradiation and additionally tested in combination with NMDAR antagonist memantine.Results: The gas exposure system proved compatible with the CFA and resulted in a stable atmosphere of 50% xenon. Indications for the presence of glutamate receptor subunits were present in glioblastoma-derived and HeLa cells. Significantly reduced clonogenic survival by xenon was shown in U87 and U251 at irradiation doses of 4–8 Gy and 2, 6 and 8 Gy, respectively (p < 0.05). Clonogenic survival was further reduced by the addition of memantine, showing a significant effect at 2–8 Gy for both glioblastoma cell lines (p < 0.05). Xenon did not significantly reduce the surviving fraction of HeLa cells until a radiation dose of 8 Gy. Conclusion: The developed system allows for testing of gaseous agents with CFA. As a proof of concept, we have, for the first time, unveiled indications of radiosensitizing properties of xenon gas in glioblastoma.